We need your help! If you've ever found our data helpful, please take our impact survey (15 min). Your replies will help keep the data flowing to the scientific community. Please Click here for Survey


Dataset Information


Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

ABSTRACT: Oncogenic mutations in RAS genes are very common in human cancer, resulting in cells with well-characterized selective advantages, but also less well-understood vulnerabilities. We have carried out a large-scale loss-of-function screen to identify genes that are required by KRAS-transformed colon cancer cells, but not by derivatives lacking this oncogene. Top-scoring genes were then tested in a larger panel of KRAS mutant and wild-type cancer cells. Cancer cells expressing oncogenic KRAS were found to be highly dependent on the transcription factor GATA2 and the DNA replication initiation regulator CDC6. Extending this analysis using a collection of drugs with known targets, we found that cancer cells with mutant KRAS showed selective addiction to proteasome function, as well as synthetic lethality with topoisomerase inhibition. Combination targeting of these functions caused improved killing of KRAS mutant cells relative to wild-type cells. These observations suggest novel targets and new ways of combining existing therapies for optimal effect in RAS mutant cancers, which are traditionally seen as being highly refractory to therapy.


PROVIDER: S-EPMC3411175 | BioStudies | 2012-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC3929229 | BioStudies
2014-01-01 | S-EPMC4110062 | BioStudies
2020-01-01 | S-EPMC7311523 | BioStudies
1000-01-01 | S-EPMC4063255 | BioStudies
2013-01-01 | S-EPMC3674106 | BioStudies
2019-01-01 | S-EPMC6774803 | BioStudies
2018-01-01 | S-EPMC6128905 | BioStudies
2013-01-01 | S-EPMC3679268 | BioStudies
2019-01-01 | S-EPMC6571060 | BioStudies
2015-01-01 | S-EPMC4599940 | BioStudies